Alzheimer’s Therapeutics: The Next Big Thing in the Healthcare Market with Advanced Technology

Trishita Deb
Trishita Deb

Updated · May 20, 2024

SHARE:

At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Learn more.
close
Advertiser Disclosure

At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us Media. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

Introduction

The projected growth of the Global Alzheimer’s Disease Therapeutics Market, with an expected expansion from USD 5.5 billion in 2023 to USD 30.8 billion by 2033, indicates a robust annual growth rate of 18.8%. This significant increase can be attributed to several factors, including an aging global population, which is likely leading to a higher incidence of Alzheimer’s disease.

Alzheimer’s disease is a neurological disorder that causes the brain to shrink (atrophy) and brain cells to die. It is the most common cause of dementia that leads to continuous decline in thinking, behavioral and social skills that affects the ability of a person to function independently. The early signs of the disease include forgetting recent events or conversations. A person with Alzheimer’s will develop severe memory impairment and lose the ability to carry out everyday tasks as the disease progresses.

The Alzheimer’s therapeutics market has shown significant growth due to the advancements in treatment, and drug discovery techniques, over the years. Moreover, the increase in demand for effective treatment of Alzheimer’s disease and therapeutic options encourages major pharmaceutical companies to invest in R&D, thus creating future growth opportunities.

In addition, the rise in awareness regarding the treatment of Alzheimer’s disease boosts the growth of the global Alzheimer’s therapeutics market. Furthermore, the presence of strong pipeline drugs is one of the factors that is projected to offer huge growth opportunities in the future.

Alzheimer’s Disease Therapeutics Market Size

To learn more about this report request a sample report PDF

The growth of the global Alzheimer’s therapeutics market size is majorly driven by the rise in the prevalence of Alzheimer’s disease across both developed and emerging countries. In addition, the growth in the occurrence of consciousness of the disease across the world and a few of the aspects such as an increase in several diagnosed patients has upsurged the need to develop therapeutics for Alzheimer’s disease. Furthermore, the availability of drugs such as Aricept, Exelon, Memantine, and Razadyne for the treatment of Alzheimer’s disease drives the growth of the market.

Moreover, as per the article published by NCBI 2019, around 121,499 deaths were recorded from Alzheimer’s disease in the U.S. The rise in several cases of Alzheimer’s disease, thus led to a rise in demand for therapeutics which significantly drives the Alzheimer’s therapeutics market growth.

Key Takeaways

  • Market Value (2023): The Alzheimer’s disease therapeutics market was valued at USD 5.5 billion in 2023.
  • Forecast Revenue (2033): By 2033, the market is projected to reach USD 30.8 billion.
  • CAGR (2024-2033): The market’s compound annual growth rate (CAGR) from 2024 to 2033 is estimated at 18.8%.
  • Regional Dominance: North America holds a significant share, accounting for 42.5% of the global Alzheimer’s disease therapeutics market in 2023.
  • Drug Class: Cholinesterase inhibitors are the dominant segment, accounting for 53.2% of the market in 2023.
  • Disease Stage: Mild cognitive impairment (MCI) is the most common stage, representing 33.7% of the market share in 2023.
  • Route of Administration: Oral administration is predominant, comprising 58.1% of the market share in 2023.
  • Distribution Channel: Hospital pharmacies hold the largest share, with 56.4% of the market in 2023.
  • Regional Analysis:
  • North America dominates the market, driven by research initiatives and government funding.
  • The Asia-Pacific region is expected to grow at the highest CAGR, fueled by increasing research activities and awareness.

Alzheimer’s Disease Therapeutics Statistics

  • The prevalence of Alzheimer’s dementia increases with age: 5% of people aged 65 to 74 have Alzheimer’s dementia.
  • 13.1% of people aged 75 to 84 have Alzheimer’s dementia.
  • 33.3% of people aged 85 or older have Alzheimer’s dementia.
  • Approximately 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia.
  • Without breakthroughs in prevention, slowing, or curing the disease, projections suggest the number of individuals with Alzheimer’s dementia could reach 13.8 million by 2060.
  • Over 11 million family members and unpaid caregivers provided approximately 18 billion hours of care to individuals with Alzheimer’s or other dementias.
  • The value of unpaid dementia caregiving was estimated at USD 339.5 billion in 2022.
  • Globally, approximately USD 55 million people are living with dementia, with projections indicating a rise to approximately USD 139 million by 2050.
  • Alzheimer Disease Statistics by Employment Status
  • Among individuals with Alzheimer’s disease, 27% are employed, while the majority, 69.8%, are retired.
  • 31.8% had diabetes.
  • Hypertension was present in 57.6%.
  • High cholesterol was reported in 39.4%.
  • Only 1.5% had a history of stroke.
  • Approximately 9.1% also had heart disease.
  • Depression was reported in 7.6%.
  • Alzheimer Disease Statistics by Race or Ethnicity
  • An estimated 11.3 million family and unpaid caregivers provided approximately 16 billion hours of informal (unpaid) assistance, valued at around USD 271.6 billion.
  • The total lifetime cost of care for a patient with dementia is estimated to be USD 412,936 in 2022 dollars.
  • United States- In the United States, it was estimated that approximately 6.5 million individuals aged 65 or older had Alzheimer’s disease in 2022.
  • United Kingdom – In the United Kingdom, it was estimated that around 850,000 people were living with dementia in 2021.
  • Australia – An estimated 472,000 people are living with dementia in Australia.
  • Canada – An estimated 564,000 Canadians are living with dementia.
  • Japan – An estimated 5.8 million people in Japan are living with dementia.
  • China- China has the largest number of people living with Alzheimer’s disease globally, with an estimated 10 million people.
  • India -An estimated USD 5.3 million people living with dementia in India.
  • Brazil- Estimated USD 1.6 million people living with dementia in Brazil.

Emerging Trends

  • Precision Medicine: Tailoring Alzheimer’s treatments to individual genetic profiles, medical histories, and lifestyles is becoming increasingly important. Advances in genomics and biomarkers are supporting this personalized approach to maximize therapeutic efficacy and minimize side effects.
  • Biomarker Development: The use of biomarkers in Alzheimer’s disease is expanding. These markers help in early and accurate diagnosis and monitor disease progression and response to treatment. Biomarkers related to brain imaging and cerebrospinal fluid are particularly promising.
  • Next-Generation Therapies: Research is focusing on beyond-amyloid targets such as tau pathology, neuroinflammation, and synaptic dysfunction. This broadens the therapeutic landscape beyond traditional amyloid-beta targeting drugs.
  • Combination Therapies: There’s an increasing interest in exploring combination therapies that simultaneously target multiple aspects of the disease. This approach aims to address the complex, multifactorial nature of Alzheimer’s.
  • Technological Integration: Digital tools and technologies, such as AI and machine learning, are being integrated into research and development processes. These technologies improve the efficiency of clinical trials and may predict disease progression and treatment responses.
  • Regulatory and Funding Enhancements: Increased funding for Alzheimer’s research and more supportive regulatory frameworks are encouraging the development of new therapies. Initiatives by various governments and private entities aim to accelerate the approval processes and increase investment in Alzheimer’s research.

Use Cases

  • Early Diagnosis and Intervention: Increasingly, Alzheimer’s therapeutics are being used in early diagnosis and intervention strategies. Biomarkers and neuroimaging are instrumental in identifying the disease in its nascent stages, which can lead to earlier and potentially more effective treatments.
  • Disease Progression Monitoring: Therapeutics are also being utilized to monitor the progression of Alzheimer’s. Regular assessments through cognitive tests and imaging can help in adjusting treatment plans and managing the disease more effectively.
  • Combination Therapies: The use of combination therapies that involve multiple drugs to target different aspects of the disease simultaneously is becoming more common. This approach aims to manage various symptoms and slow down the progression of Alzheimer’s more effectively than monotherapy.
  • Personalized Medicine: Tailoring treatment plans based on individual genetic makeup and disease manifestation is another growing use case. This approach leverages genetic information to predict how well a patient might respond to certain treatments, optimizing therapy choices.
  • Supportive Care Technologies: Beyond pharmaceuticals, there is increasing use of technologies like AI and machine learning to support diagnostic and therapeutic processes. These technologies can analyze large datasets to predict outcomes, personalize treatments, and monitor disease progression.
  • Preventive Treatments: In some cases, Alzheimer’s therapeutics are being explored for their preventive potential, particularly in individuals at high risk due to genetic factors. This proactive use involves medications that aim to delay or prevent the onset of Alzheimer’s symptoms.

Conclusion

The Alzheimer’s Disease Therapeutics Market is poised for substantial growth, with projections indicating a robust increase from USD 5.5 billion in 2023 to USD 30.8 billion by 2033, at a CAGR of 18.8%. This expansion is primarily fueled by factors such as an aging population, heightened awareness, and advancements in treatment modalities. North America leads the market, yet the Asia-Pacific region shows promising growth potential. Emerging trends like precision medicine and biomarker development are reshaping therapeutic approaches. With increased funding and regulatory support, coupled with evolving technologies, the landscape holds promise for improved diagnostics, personalized treatments, and enhanced patient care.

SHARE:
Trishita Deb

Trishita Deb

Trishita has more than 7 years of experience in market research and consulting industry. She has worked in various domains including healthcare, consumer goods, and materials. Her expertise lies majorly in healthcare and has worked on more than 400 healthcare reports throughout her career.